Concepedia

Author

M. Mauer

Institut Gustave Roussy

Also Known As

L. D. Elving, M Lentz, M Mauer, M. E. Mauer, M. Mauer, M.E. Mauer, Muriel Mauer

26

Publications

437

Citations

10

H-Index

14

Concepts

All Affiliations

Institut Gustave RoussyEuropean Organisation for Research and Treatment of CancerRoyal Marsden HospitalHospital Universitario 12 De OctubreIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
MM

About

M. Mauer is an author at Institut Gustave Roussy specializing in radiation oncology, cancer therapeutics, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

134

2

Surgical Oncology

3

3

63

3

Gastroenterology

2

2

43

4

Health Sciences

1

1

71

5

Pathology

1

1

14

M. Mauer

×

7

Publications

225

Citations

7

H-Index

YearCitations

VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study

L. Paz-Ares, E O’Brien, M. Mauer,

Annals of Oncology

2022

71

Concurrent coronary and carotid artery surgery: factors influencing perioperative outcome and long-term results†

Philippe Kolh, Laetitia Comté, Vincent Tchana‐Sato,

European Heart Journal

2005

51

Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954

C Schuhmacher, P. Schlag, Florian Lordick,

Journal of Clinical Oncology

2009

29

Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study

Florian Lordick, M. Mauer, Gertraud Stocker,

Annals of Oncology

2024

29

PG 6.2 Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: disease free survival results at interim analysis

Hans‐Joachim Schmoll, Karin Haustermans, Timothy Price,

European Journal of Cancer

2014

20

O-6 EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients (pts) with resected gastroesophageal adenocarcinoma (GEA) following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—an open-label randomized controlled phase II study

Elizabeth Smyth, M. Mauer, Chiara Alessandra Cella,

Annals of Oncology

2023

14

120MO Adjuvant pembrolizumab versus placebo for early-stage NSCLC after resection and optional chemotherapy: Updated results from PEARLS/KEYNOTE-091

Benjamin Besse, Libor Havel, Solange Peters,

Immuno-Oncology Technology

2023

11

Page 1